Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2021-12 Issue:12 Volume:22 Page:1721-1731
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Banerjee Susana,Moore Kathleen N,Colombo Nicoletta,Scambia Giovanni,Kim Byoung-Gie,Oaknin Ana,Friedlander Michael,Lisyanskaya Alla,Floquet Anne,Leary Alexandra,Sonke Gabe S,Gourley Charlie,Oza Amit,González-Martín Antonio,Aghajanian Carol,Bradley William H,Holmes Eileen,Lowe Elizabeth S,DiSilvestro Paul

Funder

Merck Sharp & Dohme Ltd

AstraZeneca plc

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

2. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer;Tewari;J Clin Oncol,2019

3. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study;De Angelis;Lancet Oncol,2014

4. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer;Kim;J Ovarian Res,2019

5. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status;Kotsopoulos;Gynecol Oncol,2016

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP;Translational Oncology;2024-11

2. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

3. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

4. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy;European Journal of Cancer;2024-09

5. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09